Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  Susan G. Komen for the Cure-AACR Outstanding Investigator Award for Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 51, 1613-1618, March 15, 1991]
© 1991 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Endo, K.
Right arrow Articles by Hakomori, S.-i.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Endo, K.
Right arrow Articles by Hakomori, S.-i.

Cell Membrane Signaling as Target in Cancer Therapy: Inhibitory Effect of N,N-Dimethyl and N,N,N-Trimethyl Sphingosine Derivatives on in Vitro and in Vivo Growth of Human Tumor Cells in Nude Mice1

Katsuyuki Endo2, Yasuyuki Igarashi, Mohammad Nisar, Qinghong Zhou and Sen-itiroh Hakomori

The Biomembrane Institute, Seattle 98119, and University of Washington, Seattle, Washington 98195

Sphingosine (SPN) has been claimed to be a negative modulator of transmembrane signaling through protein kinase C (PK-C) or some yet unidentified mechanism [for review see Y. A. Hannun and R. M. Bell, Science (Washington DC), 243: 500–507, 1989]. N,N-Dimethylsphingosine (DMS) was recently found to be a physiological cellular component and, in comparison to SPN, to show a stronger and stereospecific inhibitory effect on PK-C activity of A431 cells (for review see Y. Igarashi, Trends Glycosci. Glycotechnol., 2: 319–332, 1990; and S. Hakomori, J. Biol. Chem., 265: 18713–18716, 1990). (4E)-N,N,N-Trimethyl-D-erythro-sphingenine (TMS) is not detectable as a normal cellular component; however, it is expected to exhibit potent activity because of its quaternary ammonium ion structure, and in fact it showed much stronger inhibitory effect than DMS or SPN on PK-C activity (which plays an important role in cell growth regulation) in vitro. In view of these findings, we investigated the effects of SPN, DMS, and TMS on in vitro growth of various human carcinoma cell lines and on in vivo tumor growth in athymic nu/nu mice. Both DMS and TMS showed similar in vitro and in vivo growth inhibitory effects on tumor cells, despite the fact that TMS showed a much stronger inhibitory effect than DMS on PK-C activity of A431 cells. In contrast, SPN showed only a weak effect on in vitro cell growth and no effect on in vivo tumor growth. Tumor growth following s.c. inoculation of mice with human gastric carcinoma cell line MKN74 was inhibited in a dose-dependent manner by DMS, and tumor size was decreased after three or four consecutive daily injections of 0.5-mg doses of DMS or TMS. Increased tumor growth occurred after administration of these compounds was stopped; however, size of tumor remained significantly smaller than in groups treated with SPN or control saline. The effect of DMS or TMS on in vitro or in vivo MKN74 cell growth was stronger than that of 8-chloro-adenosine-cyclic 3':5'-monophosphate dihydrate, the most promising agent currently being used in clinical trials for inhibition of tumor growth by induction of differentiation. These results suggest that DMS or TMS could be useful anticancer agents through modification of transmembrane signaling related to cancer cell growth.

1 The study was supported by the National Cancer Institute Outstanding Investigator Grant CA42505 and by funds from The Biomembrane Institute and Otsuka Pharmaceutical Co., Ltd. This study is the first in a series of related papers.

2 Present address, Department of Surgery, Tsukuba University School of Medicine, Tsukuba, Japan.

Received 10/29/90. Accepted 1/ 7/91.




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
K. Takabe, S. W. Paugh, S. Milstien, and S. Spiegel
"Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets
Pharmacol. Rev., June 1, 2008; 60(2): 181 - 195.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Gundewar, J. W. Calvert, J. W. Elrod, and D. J. Lefer
Cytoprotective effects of N,N,N-trimethylsphingosine during ischemia- reperfusion injury are lost in the setting of obesity and diabetes
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2462 - H2471.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. J. Kim, Y. Lee, E.-J. Chang, H.-M. Kim, S.-P. Hong, Z. H. Lee, J. Ryu, and H.-H. Kim
Suppression of Osteoclastogenesis by N,N-Dimethyl-D-erythro-sphingosine: A Sphingosine Kinase Inhibition-Independent Action
Mol. Pharmacol., August 1, 2007; 72(2): 418 - 428.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
A. B. Ghering and W. S. Davidson
Ceramide structural features required to stimulate ABCA1-mediated cholesterol efflux to apolipoprotein A-I
J. Lipid Res., December 1, 2006; 47(12): 2781 - 2788.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
D. E. Modrak, D. V. Gold, and D. M. Goldenberg
Sphingolipid targets in cancer therapy.
Mol. Cancer Ther., February 1, 2006; 5(2): 200 - 208.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. C. Hait, S. Sarkar, H. Le Stunff, A. Mikami, M. Maceyka, S. Milstien, and S. Spiegel
Role of Sphingosine Kinase 2 in Cell Migration toward Epidermal Growth Factor
J. Biol. Chem., August 19, 2005; 280(33): 29462 - 29469.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. M. Woodcock, J. Murphy, F. C. Stomski, M. C. Berndt, and A. F. Lopez
The Dimeric Versus Monomeric Status of 14-3-3{zeta} Is Controlled by Phosphorylation of Ser58 at the Dimer Interface
J. Biol. Chem., September 19, 2003; 278(38): 36323 - 36327.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. A. Shabbits, Y. Hu, and L. D. Mayer
Tumor Chemosensitization Strategies Based on Apoptosis Manipulations
Mol. Cancer Ther., August 1, 2003; 2(8): 805 - 813.
[Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
E. H. Ahn and J. J. Schroeder
Sphingoid Bases and Ceramide Induce Apoptosis in HT-29 and HCT-116 Human Colon Cancer Cells
Experimental Biology and Medicine, May 1, 2002; 227(5): 345 - 353.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. M. Schmelz, P. C. Roberts, E. M. Kustin, L. A. Lemonnier, M. C. Sullards, D. L. Dillehay, and A. H. Merrill Jr.
Modulation of Intracellular {beta}-Catenin Localization and Intestinal Tumorigenesis in Vivo and in Vitro by Sphingolipids
Cancer Res., September 1, 2001; 61(18): 6723 - 6729.
[Abstract] [Full Text] [PDF]


Home page
J Oncol Pharm PractHome page
R. van Gijn, X. Zuidema, A. Bult, and J. H. Beijnen
Protein kinase C as a target for new anti-cancer agents
Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 166 - 178.
[Abstract] [PDF]


Home page
J. Nutr.Home page
H. Vesper, E.-M. Schmelz, M. N. Nikolova-Karakashian, D. L. Dillehay, D. V. Lynch, and A. H. Merrill Jr.
Sphingolipids in Food and the Emerging Importance of Sphingolipids to Nutrition
J. Nutr., July 1, 1999; 129(7): 1239 - 1250.
[Abstract] [Full Text]


Home page
Cardiovasc ResHome page
B. Campbell, Y. K. Shin, R. Scalia, and A. M. Lefer
Beneficial effects of N,N,N-trimethylsphingosine following ischemia and reperfusion in the isolated perfused rat heart
Cardiovasc Res, August 1, 1998; 39(2): 393 - 400.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Li, J. Manela, Y. Kong, and S. Ladisch
Cellular Gangliosides Promote Growth Factor-induced Proliferation of Fibroblasts
J. Biol. Chem., October 27, 2000; 275(44): 34213 - 34223.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1991 by the American Association for Cancer Research.